News & Stories

See the latest news about CMT drug development and read stories from the CMT community that highlight why we must deliver treatments and cures during our lifetime.

AcuraStem Achieves First Milestone

Sep 18, 2019 | CMT Research Updates, Press Releases, Research News

Just nine months ago, we announced a milestone-based, research collaboration with AcuraStem to test thousands of compounds aimed at producing effective treatments for CMT2A. We are very pleased to report that AcuraStem has completed phase one of the CMT2A project. To...

Roadblocks on the Road to Curing Charcot-Marie-Tooth (CMT)

Sep 11, 2019 | CMT Research Updates, Press Releases, Research News

It seems like every other day we hear about a new drug that has been approved for a rare neurologic disease. Increased understanding of the genetics underlying these diseases has led to numerous new gene therapies. Why have we not yet seen similar successes in CMT? In...

CMT1A Research Update

Sep 2, 2019 | CMT Research Updates, Press Releases, Research News

CMT1A is caused by a duplication of the PMP22 gene leading to overexpression of the PMP22 protein and failure of the Schwann cells to produce myelin (the insulation of the nerve) well. Without proper myelination, the nerves don’t send signals quickly or strongly,...

CMTRF Welcomes Dr. Grace Pavlath as Chief Science Officer

Jul 30, 2019 | Press Releases

CMT Research Foundation (CMTRF), a not-for-profit organization focused solely on delivering treatments and cures for Charcot-Marie-Tooth disease, has added Grace Pavlath, Ph.D. to the team as the new Chief Scientific Officer. CMT is a progressive genetic nerve disease...

Scenes from BIO2019

Jun 11, 2019 | Press Releases

Last week Paul August and I attended the BIO International Convention, a conference with over 16,000 leaders from the biotech and pharmaceutical industry. We met a number of companies interested in advancing drug development for CMT. There are four primary factors...

Partnerships and Priorities: The Pathway to CMT Results

May 31, 2019 | CMT Research Updates, Press Releases, Research News

From time to time the CMT Research Foundation will examine the impediments to finding a cure for CMT. As the Chairman of a nonprofit foundation whose ONLY mission is to fund research that will lead to a cure for Charcot-Marie-Tooth disease (CMT), I am often...

The Inherited Neuropathy Consortium (INC) welcomes the CMT Research Foundation as a partner in their Patient Advocacy Groups

Jan 9, 2019 | CMT Research Updates, Press Releases

Today the Inherited Neuropathy Consortium (INC) named the CMT Research Foundation as a partner in their Patient Advocacy Groups. This gives the CMT Research Foundation access to INC resources, researchers and its clinical infrastructure through 21 CMT Centers of...

Is there a connection between CMT1X and Multiple Sclerosis?

Dec 18, 2018 | About CMT, CMT Research Updates

A recent study by Georgios Koutis et al at the National and Kapodistrian University of Athens recently published a paper in The Journal of Neurology, Neurosurgery and Psychiatry suggesting emerging evidence of a connection between CMTX1 and Multiple Sclerosis (MS)....

CMT Research Foundation Adds Dr. Charles Abrams and Jeff Ellman To The Team

Dec 18, 2018 | Press Releases

CMT Research Foundation (CMTRF), focused solely on delivering treatments and cures for Charcot-Marie-Tooth disease, added Jeff Ellman to its Board of Directors and Charles Abrams MD, Ph.D, to its Scientific Advisory Board. CMT is a progressive genetic nerve disease...